Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes
Authors' conclusion
The SGLT2i and GLP1-RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.
Study context
- Population
- People with T1D on insulin
- Participants
- 296 people
- Exposure
- SGLT2i, GLP-1 RA or both added to insulin vs control
- Controln = 80reference
- SGLT2in = 94
- GLP1-RAn = 82
- Combon = 40
- Outcome
- Changes in weight and HbA1c
- Follow-up
- 1 year
Methodological detailselectronic health records
- Electronic health records
Main finding
As reported in the abstract
Percentage weight loss · 12 months
P < 0.001
- Combo lost the most weight
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2i | GLP1-RA | Combo | P value |
|---|---|---|---|---|
| HbA1c reduction · 12 monthsBetween SGLT2i and GLP1-RA · SGLT2i, GLP1-RA and Combo compared | 0.4% (SD 0.7%) | 0.3% (SD 0.7%) | 0.6% (SD 0.8%) | P < 0.001 |
Glycemic control, total and LDL-C vs baseline
- Combo had the biggest improvements vs baseline
- all p < 0.01
Safety
- Severe adverse events similar between all groups, no increased risk of DKA
Original publication
Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes. Obesity (Silver Spring). Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →